Role of Antipsychotic Agents in Dementia-Associated Neuropsychiatric Symptoms: Efficacy, Safety, and Deprescribing Strategies
Abstract
Background. Dementia syndromes involve cognitive and functional decline and frequent neuropsychiatric symptoms, including agitation, aggression, and hallucinations. These symptoms increase caregiver burden, institutionalization, and loss of quality of life. Antipsychotics remain relevant but controversial because benefits are modest and risks substantial.
Aim. This review summarizes evidence and guideline recommendations on the role, indications, monitoring and deprescribing of antipsychotics in dementia-related neuropsychiatric symptoms.
Material and methods. This narrative review was based on selected guidelines, systematic reviews, network meta-analyses, randomized trials and observational studies on antipsychotic use in dementia-related neuropsychiatric symptoms
Results. Antipsychotics should not be routine first-line treatment. Before pharmacotherapy, reversible causes such as pain, delirium, infection, dehydration, drug effects and environmental triggers should be assessed. Psychosocial and environmental interventions remain fundamental. Antipsychotics may be considered only in selected patients with severe agitation, aggression or psychosis causing distress or risk of harm. Evidence supports modest efficacy mainly for agitation and aggression, whereas effects on psychosis are less consistent. Risperidone is a well-established option for severe aggression and agitation in Alzheimer’s disease, while brexpiprazole has emerged as an option for agitation in Alzheimer’s…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.